Major Release of Veeva Site Connect Streamlines Clinical Trial Execution for Sites and Sponsors
Veeva Systems (NYSE: VEEV) has announced a major release of Veeva Site Connect, enhancing clinical trial execution for sites and sponsors. The update includes new capabilities and a streamlined site-centric experience to simplify sponsor-site collaboration. Key features include:
1. Expanded functionality beyond document exchange and safety distribution
2. Optimized site user interface standardized across all trials
3. Open accessibility for all sites globally
4. Fixed-price implementation with 2-4 month setup
Seven of the top 20 biopharmas have already adopted Veeva Site Connect, aiming to reduce time and effort in site start-up, study conduct, and closeout. The platform is part of Veeva Clinical Platform, supporting patients, sites, and sponsors in streamlining clinical trials.
Veeva Systems (NYSE: VEEV) ha annunciato un'importante release di Veeva Site Connect, migliorando l'esecuzione delle prove cliniche per i siti e gli sponsor. L'aggiornamento include nuove funzionalità e un'esperienza semplificata incentrata sui siti per facilitare la collaborazione tra sponsor e siti. Le caratteristiche principali includono:
1. Funzionalità ampliata oltre lo scambio di documenti e la distribuzione della sicurezza
2. Interfaccia utente ottimizzata per i siti, standardizzata su tutte le prove
3. Accessibilità aperta per tutti i siti a livello globale
4. Implementazione a prezzo fisso con un setup di 2-4 mesi
Sette dei primi 20 gruppi biofarmaceutici hanno già adottato Veeva Site Connect, con l'obiettivo di ridurre tempo e sforzo nella fase di avvio del sito, nella conduzione dello studio e nella chiusura. La piattaforma fa parte della Veeva Clinical Platform, che supporta pazienti, siti e sponsor nel semplificare le prove cliniche.
Veeva Systems (NYSE: VEEV) ha anunciado un lanzamiento importante de Veeva Site Connect, mejorando la ejecución de ensayos clínicos para sitios y patrocinadores. La actualización incluye nuevas capacidades y una experiencia centrada en el sitio que simplifica la colaboración entre patrocinadores y sitios. Las características clave incluyen:
1. Funcionalidad ampliada más allá del intercambio de documentos y distribución de seguridad
2. Interfaz de usuario del sitio optimizada y estandarizada en todos los ensayos
3. Accesibilidad abierta para todos los sitios a nivel global
4. Implementación a precio fijo con un plazo de preparación de 2-4 meses
Ya siete de los 20 principales biofarmacéuticos han adoptado Veeva Site Connect, con el objetivo de reducir el tiempo y esfuerzo en el inicio del sitio, la conducción del estudio y el cierre. La plataforma es parte de la Veeva Clinical Platform, que apoya a pacientes, sitios y patrocinadores en la simplificación de ensayos clínicos.
Veeva Systems (NYSE: VEEV)는 Veeva Site Connect의 주요 출시를 발표하며 연구소와 스폰서를 위한 임상 시험 실행을 향상시켰습니다. 이번 업데이트는 스폰서-사이트 간의 협업을 단순화하기 위해 새로운 기능과 사이트 중심의 경험을 포함합니다. 주요 기능은 다음과 같습니다:
1. 문서 교환 및 안전 배포를 넘어선 기능 확장
2. 모든 시험에 걸쳐 표준화된 최적화된 사이트 사용자 인터페이스
3. 전 세계 모든 사이트에 대한 개방 접근성
4. 2-4개월의 설정 기간을 가진 고정 가격 구현
상위 20개 제약회사 중 7개가 이미 Veeva Site Connect를 채택하여 사이트 시작, 연구 수행 및 종료에서 시간과 노력을 줄이는 것을 목표로 하고 있습니다. 이 플랫폼은 Veeva Clinical Platform의 일부로, 임상 시험을 간소화하는 데 있어 환자, 사이트 및 스폰서를 지원합니다.
Veeva Systems (NYSE: VEEV) a annoncé une mise à jour majeure de Veeva Site Connect, améliorant l'exécution des essais cliniques pour les sites et les sponsors. Cette mise à jour comprend de nouvelles fonctionnalités et une expérience centrée sur le site afin de simplifier la collaboration entre sponsors et sites. Les principales caractéristiques incluent :
1. Fonctionnalité élargie au-delà de l'échange de documents et de la distribution de sécurité
2. Interface utilisateur des sites optimisée, standardisée sur tous les essais
3. Accessibilité ouverte pour tous les sites dans le monde
4. Mise en œuvre à prix fixe avec un délai de préparation de 2 à 4 mois
Sept des 20 plus grandes biopharmaceutiques ont déjà adopté Veeva Site Connect, dans le but de réduire le temps et l'effort nécessaires pour le démarrage des sites, la conduite des études et la clôture. La plateforme fait partie de la Veeva Clinical Platform et soutient les patients, les sites et les sponsors dans la simplification des essais cliniques.
Veeva Systems (NYSE: VEEV) hat eine wichtige Version von Veeva Site Connect angekündigt, die die Durchführung klinischer Studien für Standorte und Sponsoren verbessert. Das Update umfasst neue Funktionen und ein standortzentriertes Erlebnis, um die Zusammenarbeit zwischen Sponsoren und Standorten zu vereinfachen. Zu den Hauptmerkmalen gehören:
1. Erweiterte Funktionalität über den Austausch von Dokumenten und Sicherheitsverteilung hinaus
2. Optimierte Benutzeroberfläche für Standorte, die auf allen Studien standardisiert ist
3. Offene Zugänglichkeit für alle Standorte weltweit
4. Festpreisimplementierung mit einer Einrichtungszeit von 2-4 Monaten
Sieben der 20 größten Biopharma-Unternehmen haben bereits Veeva Site Connect angenommen, um Zeit und Aufwand bei der Standortgründung, der Studiendurchführung und dem Abschluss zu reduzieren. Die Plattform ist Teil der Veeva Clinical Platform und unterstützt Patienten, Standorte und Sponsoren bei der Vereinfachung klinischer Studien.
- Seven of the top 20 biopharmas have adopted Veeva Site Connect
- New capabilities expand Site Connect beyond document exchange and safety distribution
- Standardized user interface for all trials, improving site efficiency
- Fixed price implementation with quick 2-4 month setup time
- Potential for significant reduction in manual processing and enhanced oversight and compliance
- None.
Insights
The release of Veeva Site Connect represents a significant advancement in clinical trial management. This platform streamlines sponsor-site collaboration, potentially reducing trial durations and costs. Key improvements include:
- Expanded capabilities beyond document exchange and safety distribution
- Standardized user interface across all trials
- Open accessibility for all sites
- Fixed-price implementation with quick turnaround
The adoption by seven of the top 20 biopharmas signals strong industry acceptance. This could lead to
Veeva's latest release showcases a strategic move in the clinical trial software market. By focusing on site-centric features and standardization, Veeva is addressing critical pain points in trial execution. The fixed-price implementation model is particularly noteworthy, as it lowers barriers to adoption for sponsors of all sizes.
This approach could significantly expand Veeva's market share and recurring revenue. With major biopharmas already on board, we might see a network effect driving further adoption. However, competitors like Medidata and Oracle Health Sciences will likely respond with similar offerings. Veeva's success will hinge on maintaining its first-mover advantage and continuously innovating to stay ahead in this
Veeva's expansion of Site Connect is a strategic move to capture more market share in the clinical trial management space. The company's focus on simplifying and standardizing site collaboration addresses a significant industry pain point, potentially leading to increased customer retention and expansion of services.
With seven of the top 20 biopharmas already adopting Site Connect, Veeva is well-positioned for revenue growth. The fixed-price implementation model could drive faster adoption, potentially accelerating revenue recognition. However, investors should monitor the impact on margins, as fixed-price models can sometimes pressure profitability. Overall, this release strengthens Veeva's competitive position and could drive long-term value creation for shareholders.
New capabilities and simple, standard site experience cut trial time and expense
Fixed price implementation to get up and running quickly
Industry advances to connected trials as seven of the top 20 biopharmas adopt Veeva Site Connect
"By standardizing how information is shared across all sites in one application with Veeva Site Connect, we aim to save time and effort that can be focused on treating patients," said a clinical operations excellence leader at a top 20 biopharma. "Our goal is to eliminate manual handoffs and inefficiencies for faster site start-up, more efficient monitoring, and simplified study closeout."
To deliver better trial execution in less time, the expansion of Veeva Site Connect includes major application and implementation advances.
- New capabilities expand Site Connect beyond document exchange and safety distribution: Veeva Site Connect adds Study Communications, Contacts, Payment Information, and quick links to sponsor systems to already powerful Document Exchange and Safety Distribution capabilities.
- Optimized site user interface that's the same for all trials: Organizing everything sites need in an intuitive site homepage with simple sidebar navigation means sites can easily stay informed and close out tasks in just a few clicks. Having the same user experience for all trials gives sites a standard way to work across sponsors.
- Open for use by any site, anywhere: Veeva Site Connect is accessible for all sites everywhere. Sites that use Veeva SiteVault as their eISF get the added benefit of connecting their study for seamless bidirectional document exchange.
- Simple fixed price implementation to get up and running in two to four months: With a standard fixed fee engagement of two to four months, depending upon company size, sponsors can make a big impact quickly toward their goal of faster, higher quality trial execution.
"I would be ecstatic if all our sponsors use Veeva Site Connect. It gives sites a much more efficient way to collaborate with sponsors, maintain regulatory compliance, and get critical therapies to patients faster," said Alisha Garibaldi, CEO, Skylight Health Research. "The less time we spend doing administrative work in systems, the more time we have to execute trials and help patients."
"By implementing Veeva Site Connect for our safety letter distribution process, we anticipate achieving a significant reduction in manual processing while enhancing oversight and compliance," said Marta Jureczko-Hinzmann, head of global clinical solution services at AstraZeneca. "Sharing safety letters across all sites globally within a single application will allow us to harmonize the entire process across the company and optimize how we allocate valuable resources."
Veeva Site Connect is part of Veeva Clinical Platform, the complete and connected solution supporting patients, sites, and sponsors. Veeva Site Connect plays a critical role as the industry moves to simplify and standardize site collaboration, and seven of the top 20 biopharmas have already adopted Veeva Site Connect to streamline trials.
See the Veeva Site Connect demo and learn more at Veeva R&D and Quality Summit September 9-10 in
Additional Information
For more on Veeva Site Connect, visit: veeva.com/VeevaSiteConnect
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2024 and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/major-release-of-veeva-site-connect-streamlines-clinical-trial-execution-for-sites-and-sponsors-302238984.html
SOURCE Veeva Systems
FAQ
What new features does Veeva Site Connect (VEEV) offer in its latest release?
How long does it take to implement Veeva Site Connect (VEEV) for sponsors?
How many top biopharma companies have adopted Veeva Site Connect (VEEV)?
What benefits does Veeva Site Connect (VEEV) offer for clinical trial execution?
